Table 3 Comparison of GVHD in three time periods

From: Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation

  19982002 N=240 (%) 20032007 N=326 (%) 20082012 N=354 (%) 20032007 20082012
     Odds ratio (95% CI) a P-value Odds ratio (95% CI) a P-value
Acute GVHD
 Grade II–IV 111 (46) 123 (38) 138 (39) 0.7 (0.50–0.99) 0.042 0.74 (0.53–1.03) 0.078
 Grade III and IV 52 (22) 47 (14) 36 (10) 0.61 (0.39–0.94) 0.026 0.41 (0.26–0.65) <0.001
 Gut stage 2–4 37 (15) 40 (12) 29 (8) 0.77 (0.47–1.24) 0.280 0.49 (0.29–0.82) <0.001
 Gut stage 3 and 4 25 (10) 28 (9) 21 (6) 0.81 (0.46–1.42) 0.460 0.54 (0.30–0.99) 0.047
 Liver stage 2–4 27 (11) 18 (6) 3 (1) 0.46 (0.25–0.86) 0.015 0.07 (0.02–0.22) <0.001
 Liver stage 3 and 4 19 (8) 11 (3) 2 (1) 0.41 (0.19–0.87) 0.020 0.07 (0.01–0.29) <0.001
 Skin stage 2–4 78 (32) 108 (33) 146 (41) 1.03 (0.72–1.47) 0.875 1.46 (1.03–2.05) 0.031
 Skin stage 3 and 4 51 (21) 80 (25) 104 (29) 1.21 (0.81–1.80) 0.360 1.54 (1.05–2.26) 0.027
Chronic GVHD
 Total 103 (43) 139 (43) 130 (37) 0.98 (0.69–1.37) 0.890 0.73 (0.52–1.02) 0.063
 Limited 33 (14) 20 (6) 25 (7) 0.40 (0.22–0.72) 0.002 0.46 (0.26–0.79) 0.005
 Extensive 70 (29) 119 (37) 105 (30) 1.37 (0.96–1.97) 0.085 0.98 (0.68–1.40) 0.89
  1. Abbreviations: GVHD=graft-versus-host disease; 95% CI=95% confidence interval.
  2. aOdds ratios compared with that in 1998–2002.